Announcements
Investor News
BioPorto A/S
BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback
Tue, 09 Jun 2026 10:28 GMT
BioPorto A/S
BioPorto planlægger amerikansk voksenvalideringsstudie efter feedback fra den amerikanske Food and Drug Administration (FDA)
Tue, 09 Jun 2026 10:28 GMT
BioPorto A/S
BioPorto announces Interim Result for the First Quarter of 2026
Thu, 21 May 2026 06:56 GMT
BioPorto A/S
BioPorto annoncerer det midlertidige resultat for første kvartal af 2026
Thu, 21 May 2026 06:56 GMT
BioPorto A/S
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
Tue, 12 May 2026 05:58 GMT
BioPorto A/S
BioPorto A/S afholder webcast for investorer om resultatet for første kvartal 2026
Tue, 12 May 2026 05:58 GMT
BioPorto A/S
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
Wed, 08 Apr 2026 13:16 GMT
BioPorto A/S
BioPorto frasælger antistofforretning til Janel Life Sciences, LLC
Wed, 08 Apr 2026 13:16 GMT
BioPorto A/S
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
Tue, 31 Mar 2026 15:43 GMT
BioPorto A/S
BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off
Tue, 31 Mar 2026 15:43 GMT